Bacitracin Inhibits the Oyster PathogenPerkinsus marinusin Vitro and in Vivo

Authors:

Abstract
The in vitro growth rates of two isolates of Perkinsus marinus were significantly reduced by bacitracin. Upon coincubation with 1 mg bacitracin/mL, the doubling times rose from 27 ± 2.1 h to 34 ± 2.9 h for the LMTX-1 isolate (P < 0.001) and from 15 ± 1.9 h to 22.2 ± 2.4 h for the Perkinsus-1 isolate (P < 0.001). At 10 mg bacitracin/mL, viability of both isolates was much reduced (P < 0.0001). The sensitivity of P. marinus to bacitracin was examined in vivo in two clinical trials. In the first, individual eastern oysters Crassostrea virginica were injected with 107 Perkinsus-1 cells, then fed bacitracin at a concentration of 5 or 50 mg/mL encapsulated in lipid vesicles daily for 6 weeks. Parasite body burden was significantly reduced in oysters administered 5 mg bacitracin/mL (3.3 × 104 ± 2.5 × 104 hypnospores/g wet tissue) or 50 mg/mL (5.3 × 104 ± 6.4 × 104 hypnospores/g) as compared with control oysters (3.2 × 105 ± 4.7 × 105 hypnospores/g, P < 0.05) that received encapsulated seawater only. In ...

This publication has 21 references indexed in Scilit: